Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

Cancer prevention research (Philadelphia, Pa.) - 1 Jan 2012

Chan Andrew T, Hsu Meier, Zauber Ann G, Hawk Ernest T, Bertagnolli Monica M

Abstract excerpt

Aspirin and celecoxib prevent colorectal adenoma recurrence. Genetic variants in the UGT1A6 enzyme are associated with delayed aspirin metabolism and greater chemopreventive efficacy. We examined the effect of combining aspirin and celecoxib in relation to UGT1A6 T181A and R184S variants among 1,647 patients in the Adenoma Prevention with Celecoxib (APC) trial who were stratified according to the use of low-dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Aspirin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Cyclooxygenase 2 Inhibitors

Share to Glucuronosyltransferase

Share to Placebos

Share to Pyrazoles

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 22030088
DOI: 10.1158/1940-6207.CAPR-11-0337
PMCID: PMC3252487

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.PMID 22030088Read ↗

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.Semantic proximity Read ↗

MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.Semantic proximity Read ↗

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.Semantic proximity Read ↗

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.Semantic proximity Read ↗

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.Semantic proximity Read ↗

Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.Semantic proximity Read ↗

Folate and MTHFR: risk of adenoma recurrence in the Polyp Prevention Trial.Semantic proximity Read ↗

Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.Semantic proximity Read ↗

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.Semantic proximity Read ↗

Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.Semantic proximity Read ↗

CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.Semantic proximity Read ↗

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.